Why Guardant Health, Inc. (GH) Soared At The Start Of The Trading Week
Guardant Health Analyst Ratings
Guardant Health (GH) Receives a Buy From Craig-Hallum
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $39 to $55
Guardant Health Up Over 22%, on Pace for Largest Percent Increase Since March 2019 -- Data Talk
Guardant Health's Strategic Milestones and Medicare Coverage Drive Buy Rating With $55 Price Target
Guardant Health Price Target Raised to $55 From $50 at BTIG
Guardant Stock Jumps 12% on Medicare Coverage Expansion
Guardant Health Receives Medicare Coverage for Guardant Reveal on Smart Liquid Biopsy Platform for Surveillance Testing in Colorectal Cancer Patients
Guardant Health, ConcertAI Collaborate On Agreement That Allows Biopharmaceutical Companies To Access The First Multi-Modal Real-World Data That Integrates Comprehensive Patient Electronic Medical Record Data With Both Genomic And Epigenomic Tumor...
Express News | Guardant Health Inc - Financial Terms of Agreement Not Disclosed
Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
Express News | Guardant Health, Concertai Collaborate to Form First Data-as-a-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
Express News | Viz.ai to Collaborate With Guardant Health to Improve Lung Cancer Detection, Diagnosis, and Treatment
Express News | Viz.ai Reveals Proposed Collaboration With Guardant Health
Craig-Hallum Maintains Guardant Health(GH.US) With Buy Rating
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $42 to $42
Guardant Health: Strong Financial Performance and Growth Potential Justify Buy Rating
Guardant Health Reports Revenue Growth Amid Cash Flow Losses
Guardant Health | 8-K: Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results